Sagent Pharma launches generic Zometa in USA; amends supply deal with Actavis

7 March 2013

Privately-held US specialty pharmaceutical company Sagent Pharmaceuticals has announced the approval and launch of zoledronic acid injection 4mg, the generic form of Swiss drug major Novartis’ (NOVN: VX) injectable bisphosphonate Zometa, used for the treatment of tumor-induced hypercalcemia, in a latex-free plastic vial.

According to IMS data, for the 12 months ending January 2013, the US market for zoledronic acid injection 4mg approximated $606 million. As with all products in Sagent's portfolio, zoledronic features Sagent's PreventIV Measures packaging and labeling, designed to help reduce medication errors.

"Sagent is pleased to offer our customers an additional source of this important product. The launch of zoledronic acid injection represents our seventh product launched at market formation," said Jeffrey Yordon, president, chief executive and chairman of Sagent.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK